Severe multiple simultaneous immune-related adverse events in a patient with head and neck cancer
Nivolumab, an immune checkpoint inhibitor (ICI) against the programmed death-1 pathway, has been used for the treatment of recurrent metastatic head and neck cancer. However, the management of immune-related adverse events (irAEs), a unique side effect of ICI therapy, can be problematic. Although severe irAEs have been reported to result from multi-ICI therapy, we report a case of multiple severe irAEs caused by single-agent nivolumab treatment. Nivolumab was administered to treat a case of hypopharyngeal cancer recurrence.
Source: Auris, Nasus, Larynx - Category: ENT & OMF Authors: Kazuma Aoki, Takao Hamamoto, Nobuyuki Chikuie, Takashi Kono, Takayuki Taruya, Takashi Ishino, Tsutomu Ueda, Sachio Takeno Tags: Case Report Source Type: research
More News: Cancer | Cancer & Oncology | ENT & OMF | Head and Neck Cancer | Hypopharyngeal Cancer | Laryngeal Cancer